Metoprolol Succinate 30 In 1 Blister Pack Breastfeeding
Breast milk is superior in nutrition, It provides resistance against infections and allergies, It is naturally sterile. Despite all the advantages of breastfeeding some mothers choose to pause the breastfeeding in fear of harmful effects of medicines passing in breast milk. Are you wondering about breastfeeding and using Metoprolol Succinate 30 In 1 Blister Pack ? Know what is Metoprolol Succinate 30 In 1 Blister Pack and how it can affect your breast milk and whether Metoprolol Succinate 30 In 1 Blister Pack is safe for your kid or not.

What is Metoprolol Succinate 30 In 1 Blister Pack used for?


Metoprolol succinate, is a beta 1-selective adrenoceptor blocking agent. Metoprolol succinate extended-release tablets, USP are indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1) Angina Pectoris. ( 1.2) Heart Failure - for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. ( 1.3) 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol succinate extended-release tablets may be administered with other antihypertensive agents. 1.2 Angina Pectoris Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Heart Failure Metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure.

What are the risk associated with Metoprolol Succinate 30 In 1 Blister Pack usage while breastfeeding? What precautions shall I take while using it in breastfeeding?

Metoprolol Succinate 30 In 1 Blister Pack safe for breastfeeding
Metoprolol tartrate is the only one ingredient used in manufacturing of Metoprolol Succinate 30 In 1 Blister Pack, Which makes it easier to analyze its effect in breastfeeding. As per our analysis of Metoprolol tartrate it is safe to use Metoprolol Succinate 30 In 1 Blister Pack while lactating. We suggest you to check further details below about Metoprolol tartrate usage in breastfeeding.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers Metoprolol is excreted in breast milk in very small quantities. An infant consuming 1 liter of breast milk daily would receive a dose of less than 1 mg of the drug. Consider possible infant exposure when metoprolol succinate extended-release tablets are administered to a nursing woman.

Metoprolol Succinate 30 In 1 Blister Pack Breastfeeding Analsys


Metoprolol tartrate while Breastfeeding

Safe

CAS Number: 51384-51-1

It is excreted into breast milk in non-significant amount without side-effects observed among infants whose mothers were taking this medication. Plasma levels in those infants were very low or undetectable. The American Academy of Pediatrics says that it is usually compatible with breastfeeding.


Metoprolol Succinate 30 In 1 Blister Pack Breastfeeding Analsys - 2


Metoprolol tartrate while Breastfeeding

CAS Number: 37350-58-6

Because of the low levels of metoprolol in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. Studies on the use of metoprolol during breastfeeding have found no adverse reactions in breastfed infants. No special precautions are required.



What if I already have used Metoprolol Succinate 30 In 1 Blister Pack?

As usage of Metoprolol Succinate 30 In 1 Blister Pack is mostly safe while breastfeeding hence there should not be any concern. In case of any change in behavior or health of your baby you should inform your health care provider about usage of Metoprolol Succinate 30 In 1 Blister Pack else no further action is required.


My health care provider has asked me to use Metoprolol Succinate 30 In 1 Blister Pack, what to do?

Definitely, Metoprolol Succinate 30 In 1 Blister Pack is safe in lactation for baby. No wonder your doctor has recommended it.


If I am using Metoprolol Succinate 30 In 1 Blister Pack, will my baby need extra monitoring?

No extra baby monitoring required while mother is using Metoprolol Succinate 30 In 1 Blister Pack


Who can I talk to if I have questions about usage of Metoprolol Succinate 30 In 1 Blister Pack in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week